IWM Overview

Market Recovery: U.S. major indexes have reversed previous losses and are trending higher.

Trump's Influence: Donald Trump has urged Israel to reduce its military strikes on Lebanon.

Market Performance: U.S. stocks experienced a reversal in intraday trading, with the Nasdaq down 0.57% and the S&P 500 off 0.17%.

Influencing Factors: The decline in stock prices was influenced by rising oil prices and increasing geopolitical tensions, which weighed on market sentiment.

Small-Cap Stocks Overview: Many top mega-cap companies began as speculative small-cap stocks, but the best stocks are those that consistently grow revenue and earnings, despite the higher volatility associated with small-cap stocks.

Market Conditions and Interest Rates: The cost of capital has increased due to higher interest rates, impacting small-cap companies that often rely on debt for growth, contrasting with previous low-interest environments.

Russell 2000 Index Performance: The Russell 2000 index, representing small-cap stocks, has seen a slight decline this year, but it has maintained solid performance over the past three years, with a significant valuation gap compared to the S&P 500.

Investment Opportunities in Small-Cap Stocks: Analysts suggest that now may be a good time to invest in Russell 2000 stocks, especially as market conditions hint at potential lower interest rates, which could attract investor interest in these stocks.

Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.

Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.

Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.

Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.

FDA Approval: Rocket Pharmaceuticals received FDA approval for its gene therapy Kresladi, aimed at treating a rare inherited pediatric disorder, marking a significant milestone for the company.

Stock Market Reaction: Following the announcement, Rocket Pharmaceuticals' stock dropped by 22%, reflecting investor concerns despite the positive FDA news.

Analyst Insights: Analysts from LifeSci Capital reiterated an 'Outperform' rating for Rocket Pharmaceuticals, suggesting that the FDA's Rare Pediatric Disease Priority Review Voucher could enhance the company's financial position significantly.

Market Sentiment: Retail sentiment around Rocket's stock remained bullish, although the stock has seen a 53% decline over the past year, indicating mixed investor confidence.

Retail Sentiment Surge: Retail chatter on Stocktwits increased by 25%, indicating a shift from 'normal' to 'high' levels of engagement, particularly around Eastman Kodak's recent performance.

Eastman Kodak's Financial Results: The company reported Q4 2025 earnings with revenues of $290 million, reflecting a 9% growth, and operational earnings before interest, tax, depreciation, and amortization (EBITDA) increased by 144%.

Stock Price Milestone: Kodak's shares surged over 12% on Friday, briefly surpassing the $10 mark for the first time since June 2021, garnering significant attention from retail traders.

Improved Financial Position: Kodak reduced its annual interest expense by approximately $40 million, resulting in a stronger balance sheet, with a cash balance of $337 million as of December 31, 2025, and more cash than debt for the first time in years.